Spontaneous perforation of the tympanic membrane in the first 10 days of life.
Twelve cases of neonates admitted to the neonatal unit of our hospital, between January 1, 2000, and December 31, 2005, because of otorrhea due to spontaneous perforation of the tympanic membrane within the first 10 days of life are presented. Data were collected retrospectively from medical records. Cultures of the middle ear exudate grew PSEUDOMONAS AERUGINOSA in 10, SERRATIA MARCENSCENS in 1, and STAPHYLOCOCCUS AUREUS in 1 neonate. Cultures of nasopharyngeal secretions grew P. AERUGINOSA in nine, S. MARCENSCENS in one, S. AUREUS in one, and STREPTOCOCCUS VIRIDANS in one neonate. Middle ear versus nasopharyngeal secretions cultures grew the same organism in 11 neonates. A 10-day course of parenteral antibiotics was administered (ampicillin-ceftazidime for all neonates except for the one neonate with the S. AUREUS otitis who received netilmicin-cloxacillin). All neonates had uneventful course and were discharged home in good clinical condition. Our findings suggest that neonates with eardrum perforation should receive antibiotics parenterally, as the most common pathogens is P. AERUGINOSA, for which there are no satisfactory antibiotics for oral use.
Iacovidou
Nicoletta
N
NICU, 2nd Department of Paediatrics, University of Athens, Aglaia Kyriakou Children's Hospital, Athens, Greece. niciac@otenet.gr
Falaena
Vasiliki
V
Alexaki
Augustina
A
Nika
Angeliki
A
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D008826:Microbial Sensitivity Tests; D010035:Otitis Media, Suppurative / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D016868:Serratia Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D012706:Serratia marcescens / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity; D013290:Streptococcal Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology; D016896:Treatment Outcome; D018058:Tympanic Membrane Perforation / Q000209:etiology* / Q000382:microbiology* / Q000503:physiopathology / Q000628:therapy; D034363:Viridans Streptococci / Q000187:drug effects / Q000302:isolation & purification / Q000472:pathogenicity
D000900:Anti-Bacterial Agents